You are viewing a preview of...
Topoisomerase 1 (Top1) Inhibition as a Novel Treatment Strategy for Sepsis and Cytokine Release Syndrome
This technology is a novel therapeutic approach to the use of a topoisomerase inhibitor to suppress the inflammatory response to infection.

Background
Sepsis is a life-threatening condition caused by an excessive host response to infection, which in turn leads to multi-organ failure and death. Estimates indicate that 250,000 to 500,000 people die from sepsis annually in the United States. To date there has been no targeted treatment for sepsis, or for other infections that promote this inflammatory storm. Researchers have discovered that chemical inhibition of Top1, an enzyme that unwinds DNA, also blocks a set of genes that are activated immediately by immune cells to combat an infection. In vitro, depletion or chemical inhibition of Top1 in epithelial cells and macrophages suppresses the host response against Influenza and Ebola viruses as well as bacterial products. In vivo, Top1 inhibition therapy rescued
Log in or create a free account to continue reading